AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
08 Apr 2016 07:00 AM
RNS
AZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIAL
01 Apr 2016 11:30 AM
RNS
Total Voting Rights
29 Mar 2016 07:00 AM
RNS
TAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTS
24 Mar 2016 03:00 PM
RNS
Director/PDMR Shareholding
23 Mar 2016 07:00 AM
RNS
AZ reports results from Brilinta stroke trial
18 Mar 2016 10:30 AM
RNS
Notice of AGM
08 Mar 2016 06:29 PM
RNS
Filing of Form 20-F with SEC
08 Mar 2016 12:00 PM
RNS
Annual Financial Report
01 Mar 2016 02:30 PM
RNS
Total Voting Rights
29 Feb 2016 01:45 PM
RNS
AZ REPORTS TOP-LINE RESULT OF TREMELIMUMAB TRIAL
29 Feb 2016 07:59 AM
RNS
AZ enters licensing agreement with CMS for Plendil
26 Feb 2016 12:00 PM
RNS
Director/PDMR Shareholding
25 Feb 2016 08:57 AM
RNS
ACALABRUTINIB ORPHAN DRUG DESIGNATION RECOMMENDED
19 Feb 2016 07:05 AM
RNS
BRILIQUE APPROVED IN EU FOR HEART ATTACK PATIENTS
19 Feb 2016 07:00 AM
RNS
ZURAMPIC APPROVED IN EU FOR GOUT PATIENTS
17 Feb 2016 07:00 AM
RNS
Durvalumab granted BTD by FDA for cancer patients
16 Feb 2016 08:01 AM
RNS
NEW EXTERNAL BOARD APPOINTMENT
04 Feb 2016 07:00 AM
RNS
AstraZeneca Full-Year and Q4 2015 Results
03 Feb 2016 09:00 AM
RNS
Notice of Results
03 Feb 2016 07:00 AM
RNS
TAGRISSO approved in EU for cancer patients
02 Feb 2016 09:05 AM
RNS
AZ Completes transaction with Acerta Pharma
01 Feb 2016 02:32 PM
RNS
Total Voting Rights
28 Jan 2016 07:00 AM
RNS
Lynparza Granted BTD in US for Prostate Cancer
04 Jan 2016 02:00 PM
RNS
Director/PDMR Shareholding
04 Jan 2016 02:00 PM
RNS
Director/PDMR Shareholding
04 Jan 2016 01:30 PM
RNS
Total Voting Rights
23 Dec 2015 04:30 PM
RNS
Result of External Audit Tender
23 Dec 2015 07:00 AM
RNS
LESINURAD APPROVED BY US FDA FOR GOUT
18 Dec 2015 12:41 PM
RNS
TAGRISSOT (OSIMERTINIB) POSITIVE CHMP OPINION
18 Dec 2015 12:41 PM
RNS
BRILIQUE (TICAGRELOR) POSITIVE EU CHMP OPINION
18 Dec 2015 12:40 PM
RNS
CHMP ISSUES POSITIVE OPINION ON LESINURAD FOR GOUT
18 Dec 2015 07:00 AM
RNS
ATLANTIC TRIAL SUPPORTS CLINICAL ACTIVITY
17 Dec 2015 02:08 PM
RNS
ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA
17 Dec 2015 07:00 AM
RNS
AZ INVESTS IN ACERTA PHARMA TO ENHANCE GROWTH
16 Dec 2015 07:12 AM
RNS
AZ ACQUISITION OF TAKEDA'S RESPIRATORY BUSINESS
15 Dec 2015 03:06 PM
RNS
AZ COMPLETES AGREEMENT WITH PERRIGO
14 Dec 2015 07:56 AM
RNS
Discussions with Acerta Pharma BV
02 Dec 2015 07:00 AM
RNS
Late-Stage Pipeline Conference Call
01 Dec 2015 02:00 PM
RNS
Blocklisting Interim Review
01 Dec 2015 01:00 PM
RNS
Total Voting Rights
23 Nov 2015 07:00 AM
RNS
AZ enters agreement w/ Perrigo for Entocort in US
13 Nov 2015 03:06 PM
RNS
AZD9291 Approved by the US FDA
11 Nov 2015 07:30 AM
RNS
ASTRAZENECA PRICES A $6 BILLION BOND ISSUE
06 Nov 2015 07:00 AM
RNS
AZ acquires ZS Pharma to strengthen CVMD portfolio
05 Nov 2015 07:02 AM
RNS
3rd Quarter Results
04 Nov 2015 09:00 AM
RNS
Notice of Results
02 Nov 2015 01:01 PM
RNS
Total Voting Rights
27 Oct 2015 05:50 PM
RNS
Director/PDMR Shareholding
26 Oct 2015 07:00 AM
RNS
FDA AD COM RECOMMENDS THE APPROVAL OF LESINURAD
16 Oct 2015 07:00 AM
RNS
Saxa/dapa FDC Complete Response Letter from FDA

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings